MARCO ANTONIO SCANAVINI FILHO
Projetos de Pesquisa
Unidades Organizacionais
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina
14 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 14
- The Use of Oral Beta-Blockers and Clinical Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: a Long-Term Follow-Up Study(2018) NICOLAU, Jose C.; FURTADO, Remo H. M.; BARACIOLI, Luciano M.; LARA, Livia M.; DALCOQUIO, Talia F.; SCANAVINI JUNIOR, Marco A.; PEREIRA, Cesar A. C.; LIMA, Viviane M.; GONCALVES, Talita M.; COLODETTI, Raiza; FERRARI, Aline G.; LOPES, Renato D.; GIUGLIANO, Robert P.BackgroundThe role of beta-blockers in patients with acute coronary syndromes is mainly derived from studies including patients with ST-segment elevation myocardial infarction. Little is known about the use of beta-blockers and associated long-term clinical outcomes in patients with non-ST-elevation acute coronary syndromes (NSTEACS).MethodsWe analyzed short- and long-term clinical outcomes of 2921 patients with NSTEACS using or not oral beta-blockers in the first 24h of the acute coronary syndromes (ACS) presentation. The association between beta-blocker use and mortality was assessed using a propensity score adjusted analysis (N=1378).ResultsPatients starting oral beta-blockers in the first 24h of hospitalization, compared with patients who did not, had lower rates of in-hospital mortality (OR=0.52, 95% CI 0.33 to 0.74, P=0.002) and higher mean survival times in the long-term follow-up (11.860.4years vs. 9.92 +/- 0.39years, P<0.001).Conclusion The use of beta-blockers in the first 24h of patients presenting with NSTEACS was associated with better in-hospital and long-term mortality outcomes.
conferenceObject EFFECT OF TICAGRELOR AND CLOPIDOGREL ON CORONARY MICROCIRCULATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION(2019) SCANAVINI FILHO, Marco Antonio; BERWANGER, Otavio; MATHIAS JUNIOR, Wilson; AGUIAR, Miguel Osman; CHIANG, Hsu Po; BARACIOLI, Luciano Moreira; LIMA, Felipe Gallego; MENEZES, Fernando Reis; DALCOQUIO, Talia; FURTADO, Remo Holanda M.; LUCA, Fabio Augusto De; UEZATO, Delcio; RAMIRES, Jose Antonio Franchini; KALIL FILHO, Roberto; NICOLAU, Jose CarlosconferenceObject Do women have worse response to P2Y12 antagonists than men after acute coronary syndrome?(2016) NICOLAU, J. C.; FERRARI, A. G.; DALCOQUIO, T.; FURTADO, R. H. M.; SCANAVINI, M. A.; NAKASHIMA, C. A. K.; ARANTES, F. B. B.; MENEZES, F. R.; LIMA, F. G.; BARACIOLI, L. M.; STRUNZ, C. M. C.; RAMIRES, J. A. F.; KALIL, R.conferenceObject Atrial fibrillation as a cornerstone of laminopathy(2018) CALIL, Z. O.; PESSENTE, G. A.; SACILOTTO, L.; OLIVETTI, N. Q. S.; HACHUL, D. T.; WU, T. C.; GRUPPI, C. J.; CARVALHO, M. L. P.; ARANHA, A. F.; PEDROSA, A. A. A.; HARDY, C. A.; PISANI, C. F.; PEREIRA, A. C.; SCANAVACCA, M. I.; DARRIEUX, F. C. C.conferenceObject Adenosine Plasmatic Concentration in Coronary Artery Disease Patients With and Without Chronic Kidney Disease(2019) FRANCI, Andre; BARBOSA, Carlos; DALCOQUIO, Talia; SALSOSO, Rocio; FURTADO, Remo H.; STRUNZ, Celia; GENESTRETI, Paulo; LIMA, Viviane; SCANAVINI, Marco; FERRARI, Aline G.; BARACIOLI, Luciano; NICOLAU, Jose C.conferenceObject INCREASED BODYWEIGHT AND INADEQUATE RESPONSE TO ASPIRIN IN INDIVIDUALS WITH CORONARY ARTERY DISEASE(2019) FURTADO, Remo Holanda de Mendonca; ARANTES, Flavia; BARBOSA, Carlos; FRANCI, Andre; MENEZES, Fernando; SALSOSO, Rocio; DALCOQUIO, Talia; NAKASHIMA, Carlos; SCANAVINI FILHO, Marco; FERRARI, Aline; GENESTRETI, Paulo; BARACIOLI, Luciano; NICOLAU, Jose C.conferenceObject Mean platelet volume and platelet reactivity in acute coronary syndromes: is there a correlation?(2016) NICOLAU, J. C.; DALCOQUIO, T. F.; FERRARI, A. G.; FURTADO, R. H. M.; NAKASHIMA, C. A. K.; SCANAVINI, M. A.; ARANTES, F. B. B.; MENEZES, F. R.; BARACIOLI, L. M.; RAMIRES, J. A. F.; STRUNZ, C. M. C.; KALIL, R.conferenceObject Predictors of returning to work in the long-run after an acute coronary syndrome episode(2018) NICOLAU, J. C.; LARA, L.; DALCOQUIO, T.; BARACIOLI, L. M.; FURTADO, R. H. M.; FRANCI, A.; COSTA, M. S. S.; FERRARI, A. G.; SCANAVINI FILHO, M. A.; GODOY, L. C.; RAMIRES, J. A. F.; KALIL-FILHO, R.; SILVA, J. C.conferenceObject Impact of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes and Reduced Left Ventricular Ejection Fraction(2019) SALSOSO, Rocio; GENESTRETI, Paulo; FRANCI, Andre; DALCOQUIO, Talia; NAKASHIMA, Carlos A.; SCANAVINI, Marco; FERRARI, Aline G.; FURTADO, Remo H.; LIMA, Felipe G.; GIRALDEZ, Roberto R.; BARACIOLI, Luciano; NICOLAU, Jose C.- Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease(2019) FURTADO, Remo H. M.; GIUGLIANO, Robert P.; DALCOQUIO, Talia F.; ARANTES, Flavia B. B.; BARBOSA, Carlos J. D. G.; GENESTRETI, Paulo R. R.; FRANCI, Andre; MENEZES, Fernando R.; NAKASHIMA, Carlos A. K.; SCANAVINI FILHO, Marco A.; FERRARI, Aline G.; SALSOSO, Rocio; BARACIOLI, Luciano M.; NICOLAU, Jose C.Recent reports have suggested that aspirin effect might be influenced by bodyweight, with decreased efficacy in heavier individuals. We investigated the influence of bodyweight on aspirin pharmacodynamics in two independent datasets of patients taking non-enteric coated aspirin 100mg QD for coronary artery disease (CAD). In the first dataset, 368 patients had their platelet aggregation assessed using VerifyNow Aspirin and measured in Aspirin Reaction Units (ARU). In the second dataset, 70 patients had serum thromboxane B2 (TXB2) dosage assessed by an ELISA assay and measured in pg/mL. Platelet aggregation was independently associated with bodyweight, with 8.41 (95% CI 1.86-14.97; adjusted p-value=0.012) increase in ARU for every 10kg. Furthermore, the rate of non-response to aspirin (defined as ARU550) was significantly associated with increased bodyweight (adjusted p-value=0.007), with OR=1.23 (95% CI 1.06-1.42) for every 10kg. Similar results were found considering body mass index (in kg/m(2)), with 15.5 (95% CI 5.0 to 25.9; adjusted p-value=0.004) increase in ARU for every 10kg and non-response OR=1.43 (95% CI 1.13 to 1.81, adjusted p-value=0.003) for every 5kg/m(2). Moreover, serum TXB2 was higher in patients weighting more than 70kg (222.6 +/- 62.9 versus 194.9 +/- 61.9pg/mL; adjusted p-value=0.018). In two different datasets of patients with CAD on non-enteric coated aspirin 100mg QD, increased bodyweight was independently associated with impaired response to aspirin.